News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
Novo Nordisk Increases Dosage in Weight Loss Drug Test, Showing Improvement but Still Behind Eli Lilly's Rival Drug
Danish pharma company Novo Nordisk A/S (NVO.US) increased the dosage of its obesity treatment drug by 3x in a clinical trial, resulting in better weight loss outcomes for patients,...
Reset
Send
The window will close in 5 seconds
Novo Nordisk Increases Dosage in Weight Loss Drug Test, Showing Improvement but Still Behind Eli Lilly's Rival Drug
Close
Recommend
3
Positive
8
Negative
3
 
SHORT SELL
 
STOCK INFO

Danish pharma company Novo Nordisk A/S (NVO.US)      increased the dosage of its obesity treatment drug by 3x in a clinical trial, resulting in better weight loss outcomes for patients, according to the Financial Times.

The Company's semaglutide was tested at a dosage of 7.2 mg in two late-stage clinical trials, which is three times the currently approved maximum dose of 2.4 mg.

Related NewsCore Inflation Rate MoM for Aug in United States is 0.3%, unchanged from its last period. The forecast was 0.3%.
Results show that patients lost an average of 19% of their body weight after 72 weeks, still trailing behind Eli Lilly and Company (LLY.US)      's tirzepatide, which reported an average weight loss of 22.5%. However, experts suggested that, if competitively priced, the 7.2 mg semaglutide could represent a more affordable alternative.
(Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)

AASTOCKS Financial News
Website: www.aastocks.com
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.